PP
ONCY

Pacifica Partners’s Oncolytics Biotech ONCY Stock Holding History

Pacifica Partners’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$101 – 534
2024
Q2 		$101 Buy
+100
New +$109 ﹤0.01% 525

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Pacifica Partners's ONCY Position: Q3 2024 in Review

Pacifica Partners sold out of Oncolytics Biotech (ONCY) in Q3 2024, closing a stake of 100 shares — an estimated $101 sold.

Pacifica Partners first reported a position in ONCY in Q2 2024 and held it in 1 quarter. The position peaked at $101 in Q2 2024. 42 funds tracked by Wall St. Rank hold ONCY as of Q3 2024.

  • Pacifica Partners reported no remaining Oncolytics Biotech position as of Q3 2024 after selling out during the quarter.
  • Pacifica Partners sold 100 Oncolytics Biotech shares in Q3 2024, an estimated $101.
  • Pacifica Partners first reported a position in Oncolytics Biotech in Q2 2024 and held it in 1 quarter.
  • Pacifica Partners's Oncolytics Biotech position peaked at $101 in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2024.

Based on Pacifica Partners's 13F filing for Q3 2024, filed 7 Oct 2024.